Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period.

Journal of hepatology - 1 Mar 2013

Bárcena Rafael, Moreno Ana, Rodríguez-Gandía Miguel Angel, Albillos Agustín, Arocena Carlos, Blesa Carlos, García-Hoz Fernando, Graus Javier, Nuño Javier, López-Hervás Pedro, Gajate Luis, Martínez Adolfo, Bermejo Teresa, Mateos María Luisa, Del Campo Santos

Abstract excerpt

BACKGROUND & AIMS: Reinfection of the graft is the rule in patients with HCV cirrhosis undergoing liver transplantation, and HCV-RNA reaches pre-transplantation levels within the first month. Short-term intravenous silibinin monotherapy is safe and shows a potent in vivo anti-HCV effect. We aimed at evaluating the safety and antiviral effect of prolonged intravenous silibinin, started immediately before liver...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Liver Transplantation

Share to Pilot Projects

Share to RNA, Viral

Source

Identifiers

PMID: 23073223
DOI: 10.1016/j.jhep.2012.10.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period.PMID 23073223Read ↗

Combination therapy with silibinin, pegylated interferon and ribavirin in a patient with hepatitis C virus genotype 3 reinfection after liver transplantation: a case report.Semantic proximity Read ↗

Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study.Semantic proximity Read ↗

Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients.Semantic proximity Read ↗

Hepatitis C treatment in patients on the liver transplant waiting list.Semantic proximity Read ↗

Management of hepatitis C after transplantation: a long way from success.Semantic proximity Read ↗

Understanding silibinin's modes of action against HCV using viral kinetic modeling.Semantic proximity Read ↗

Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.Semantic proximity Read ↗

Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant.Semantic proximity Read ↗

Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.Semantic proximity Read ↗

Intravenous interferon administered during liver transplantation is not effective in preventing hepatitis C reinfection.Semantic proximity Read ↗

Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B.Semantic proximity Read ↗

Hepatitis C virus in the transplant setting.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.